{
 "name": "樂迦再生",
 "slug": "tw-6891",
 "aliases": [
  "樂迦再生科技股份有限公司",
  "Locus Cell",
  "6891"
 ],
 "ticker": "6891",
 "industry": "生技醫療業",
 "website": "http://www.locus-cell.com/",
 "summary": "樂迦再生（6891）是興櫃的生技醫療類股公司，2020 年成立，2022 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "樂迦再生科技股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Locus Cell",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2022-04-28",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2020-10-15",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "邱俊榮",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "張裕享",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 2006422500,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "安侯建業聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "http://www.locus-cell.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：Elate Ocular（異體人類血小板裂解液hPL）",
   "value": "中重度乾眼症／免疫相關眼表病變｜承接客戶三期臨床試驗製造需求｜台灣（製造布局）／美國（開發）",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/689120260825M001.pdf",
   "note": "Cambium Bio客戶產品；公司角色為CDMO，非自有藥物；第18至20頁。"
  },
  {
   "claim": "管線：Zamto-cel（tandem CD20-CD19 CAR-T）",
   "value": "復發／難治型B細胞惡性腫瘤｜CDMO技術轉移進行中（2026年7月赴德）｜台灣／亞太製造布局",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/689120260825M001.pdf",
   "note": "Miltenyi客戶療法；非樂迦自有藥物，非上市核准；第21至22頁。"
  },
  {
   "claim": "催化劑：竹北細胞製造廠",
   "value": "美國FDA查廠（公司預估）｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-08-25",
   "source": "https://mopsov.twse.com.tw/nas/STR/689120260825M001.pdf",
   "note": "第20頁公司預計2027年FDA查廠，並非FDA公開承諾日期。"
  },
  {
   "claim": "管線：人類血球來源誘導性多潛能幹細胞iPSC外泌體",
   "value": "化妝品原料用途｜取得PCPC國際INCI原料認證38479並接獲委託訂單｜國際市場",
   "unit": "",
   "as_of": "2025-04-30",
   "source": "https://www.locus-cell.com/download/shareholder/%e6%a8%82%e8%bf%a6_2025%e5%b9%b4%e8%82%a1%e6%9d%b1%e5%b8%b8%e6%9c%83%e5%b9%b4%e5%a0%b1_Final.pdf",
   "note": "封面刊印日期2025-04-30；第3及5頁。INCI為化妝品原料命名認證，不是藥品許可或療效認證。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-6891.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}